The Predictive Value of Tumor Microenvironment PET/CT Imaging for Treatment Response and Prognosis in Aggressive Lymphoma: A Multicenter Clinical Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 94
- 试验地点
- 1
研究概览
简要总结
This multicenter study aims to evaluate the predictive value of tumor microenvironment PET/CT imaging for treatment response and prognosis in patients with aggressive lymphoma. Eligible patients with histologically confirmed aggressive lymphoma will undergo FAPI PET/CT imaging, and selected patients who are candidates for immunotherapy will undergo Grazytracer PET/CT imaging. These imaging methods are intended to assess fibroblast activation protein expression and granzyme B activity in lymphoma lesions, reflecting cancer-associated fibroblasts and cytotoxic T-cell activity in the tumor microenvironment. The study will explore optimal imaging assessment criteria and develop clinical-pathological-imaging models to predict treatment response, prognosis, and the relationship between tumor heterogeneity and refractory or relapsed disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed aggressive lymphoma.
- •Baseline PET/CT showing moderate to high FDG uptake in lymphoma lesions.
- •No previous history of malignant tumors.
- •No significant cardiac, hepatic, or renal dysfunction.
- •Expected survival of at least 6 months and ability to complete follow-up.
排除标准
- •Low FDG uptake on baseline PET/CT.
- •Lymphoma lesions have been surgically removed, with no positive lesions available for evaluation.
- •Active or uncontrolled chronic inflammation or infection.
- •Uncontrolled diabetes mellitus.
- •Incomplete clinical data or loss to follow-up.
- •Refusal to sign the informed consent form.
- •Inability to lie supine for 30 minutes.